NONOF - Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

2024-06-10 12:48:37 ET

Summary

• Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome.
• The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS.
• The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029.
• Keros Therapeutics is also developing the use of KER-050 for the treatment of patients with myelofibrosis and data from the phase 2 study for this program is expected in Q4 2024.

Keros Therapeutics, Inc. ( KROS ) is gearing up to report long-term results from its phase 2 study using KER-050 [elritercept] for the treatment of patients with myelodysplastic syndrome [MDS]. Matter of fact, it is expected that it will present 5 abstracts at the upcoming 29th Annual Congress of the European Hematology Association [EHA] medical conference between June 13th - 16th of 2024. This is one catalyst that investors might want to keep an eye on, where it is possible that shareholder value could be increased because of all of this data to be presented.

However, there is so much more based on this program beyond what is to be shown with the release of these 5 abstracts. It has already met with the FDA and both have concluded on a design to be used for a phase 3 study, using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome [LR-MDS]....

For further details see: